• June 17, 2021

About us

Methexis Genomics NV is a Ghent, Belgium-based genomics company dedicated to the development of proprietary technologies for improving the efficiency and reducing the cost of genetic variation analysis in human health and agriculture applications.

Methexis Genomics has conceptualized and protected a novel insight into the fundamental structure of genetic variation – ‘the SPC concept’ (Sequence Polymorphism Clusters) – which is fundamentally different from the haplotype block concept. The SPC map of a chromosomal region of interest or of an entire genome provides a rational framework to identify and select the diagnostically most informative SNP (Single Nucleotide Polymorphism) markers for genetic analysis. Based on the latest HapMap genotype data, Methexis identified a core collection of 55,000 ‘super-tagSNPs’ for human genome-wide association studies.

The Company has also developed an innovative method for high-performance DNA sequence analysis based on the mass spectrometry platform. This comparative sequencing method allows the identification and mapping of both known and unknown sequence variations, relative to a related reference sequence.

Methexis Genomics has entered into a collaborative and commercial agreement with Sequenom (San Diego, CA) on the basis of this proprietary DNA analysis method. A first kit and accompanying software are available for SNP discovery using the MassARRAY system. Other applications of the technology are under development.

Methexis Genomics has built a state-of-the-art service facility equipped with the latest MassARRAY system components and multiple robotic platforms. The MassARRAY based genetic analysis services that are offered include applications that make use of Sequenom’s MassEXTEND (hME) assay as well as applications based on Methexis Genomics’ innovative method for nucleic acid fragmentation, i.e. the MassCLEAVE (hMC) assay. We are currently in the process of designing and validating MassEXTEND assays for the above-mentioned collection of ~55,000 ‘super-tagSNPs’. These assays will be applied through association study collaborations.